Article3 Biotech2024
Methanolic extract of wheatgrass (
Article in 3 Biotech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study examined the anti-inflammatory and functional improvement of the uterus and ovary, respectively, in bisphenol-A (BPA)-fed adult Wistar rats following the ingestion of methanolic extract of wheatgrass (WG-ME). Four groups of rats were conditioned as vehicle-treated control, BPA-treated (100 mg/kg b.w.), BPA + WG-ME (100 mg BPA/kg b.w. + 200 mg WG-ME/kg b.w.), and WG-ME (200 mg/kg b.w.) groups. The LC-MS study confirmed the presence of numerous bioactive components in WG-ME. ELISA, PAGE, real-time PCR, and immunohistostaining were executed to test the efficacy of WG-ME against BPA. WG-ME was shown to induce significant weight gain of the uterus and ovaries as well as improve the estrous cycle and antioxidant status. WG-ME effectively suppressed the mRNA expression of TNF-α (tumor necrosis factor-alpha) and NF-κB (nuclear factor kappa-B). This extract also increased the expression of the antiapoptotic factor BCL2 (B-cell lymphoma 2) in the uterine tissue of rats administered BPA while impeding the abnormal expression of the tumor proteins p53, cylcin-D1, and BAX (BCL2-associated protein X). An enhanced steroidogenic event was supported by improved gonadotropins and reproductive hormone levels, feeble signaling of androgen receptors, and improved ovarian follicular growth with a distinct appearance of granulosa layer as well as better uterine histomorphology. The abundance of apigenin and catechin compounds in WG-ME may potentiate the above effects. The molecular interaction study predicted that apigenin inhibits TNF-α by interacting with its major site. Hence, WG-ME may exert its preventive efficacy in managing the functional imbalance of reproductive organs caused by BPA. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-024-04117-0.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.